Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Transplantation ; 107(12): e339-e347, 2023 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-37726882

RESUMEN

BACKGROUND: In the context of the organ shortage, donation after circulatory death (DCD) provides an opportunity to expand the donor pool. Although deceased-donor liver transplantation from DCD donors has expanded, DCD livers continue to be discarded at elevated rates; the use of DCD livers from older donors, or donors with comorbidities, is controversial. METHODS: Using US registry data from 2009 to 2020, we identified 1564 candidates on whose behalf a DCD liver offer was accepted ("acceptors") and 16 981 candidates on whose behalf the same DCD offers were declined ("decliners"). We characterized outcomes of decliners using a competing risk framework and estimated the survival benefit (adjusted hazard ratio [95% confidence interval]) of accepting DCD livers using Cox regression. RESULTS: Within 10 y of DCD offer decline, 50.9% of candidates died or were removed from the waitlist before transplantation with any type of allograft. DCD acceptors had lower mortality compared with decliners at 10 y postoffer (35.4% versus 48.9%, P < 0.001). After adjustment for candidate covariates, DCD offer acceptance was associated with a 46% reduction in mortality (0.54 [0.49-0.61]). Acceptors of older (age ≥50), obese (body mass index ≥30), hypertensive, nonlocal, diabetic, and increased risk DCD livers had 44% (0.56 [0.42-0.73]), 40% (0.60 [0.49-0.74]), 48% (0.52 [0.41-0.66]), 46% (0.54 [0.45-0.65]), 32% (0.68 [0.43-1.05]), and 45% (0.55 [0.42-0.72]) lower mortality risk compared with DCD decliners, respectively. CONCLUSIONS: DCD offer acceptance is associated with considerable long-term survival benefits for liver transplant candidates, even with older DCD donors or donors with comorbidities. Increased recovery and utilization of DCD livers should be encouraged.


Asunto(s)
Trasplante de Hígado , Obtención de Tejidos y Órganos , Humanos , Estados Unidos , Trasplante de Hígado/efectos adversos , Donadores Vivos , Donantes de Tejidos , Hígado , Trasplante Homólogo , Supervivencia de Injerto , Muerte , Estudios Retrospectivos
2.
Acta Trop ; 211: 105606, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32598923

RESUMEN

Combination therapy has been proposed as an ideal strategy to reduce drug toxicity and improve treatment efficacy in Chagas disease. Previously, we demonstrated potent in vivo anti-Trypanosoma cruzi activity of voriconazole. In this work, we aimed to study the synergistic effect of voriconazole (VCZ) and benznidazole (BZ) both in vitro and in vivo models of T. cruzi infection using the Tulahuen strain. Combining VCZ and BZ at fixed concentrations, the inhibitory concentration 50% (IC50) on amastigotes was lower than the obtained IC50 for BZ alone and the Fractional Inhibitory Concentration Index (∑FIC) suggested an in vitro additive effect on T. cruzi amastigotes inhibition at concentrations devoid of cytotoxic effects. Treatment response in the in vivo model was evaluated by comparing behavior and physical aspects, parasitemia and mortality of mice infected with Tulahuen strain. VCZ and BZ treatments alone or in combination were well tolerated. All treated animals displayed significantly lower mean peak parasitemia and mortality compared to infected non-treated controls (p< 0.05). However, VCZ + BZ combination elicited no additional benefits over BZ monotherapy. VCZ efficacy was not enhanced by combination therapy with BZ at the doses studied, requiring further and astringent non-clinical studies to establish the VCZ efficacy and eventually moving forward to clinical trials.


Asunto(s)
Enfermedad de Chagas/tratamiento farmacológico , Nitroimidazoles/farmacología , Nitroimidazoles/uso terapéutico , Parasitemia/tratamiento farmacológico , Tripanocidas/farmacología , Tripanocidas/uso terapéutico , Voriconazol/uso terapéutico , Animales , Chlorocebus aethiops , Sinergismo Farmacológico , Técnicas In Vitro , Ratones , Trypanosoma cruzi/efectos de los fármacos , Células Vero/efectos de los fármacos , Voriconazol/farmacología
3.
Diabetes ; 66(8): 2230-2240, 2017 08.
Artículo en Inglés | MEDLINE | ID: mdl-28483802

RESUMEN

This study tested the hypothesis that glucagon-like peptide 1 (GLP-1) therapies improve cardiac contractile function at rest and in response to adrenergic stimulation in obese swine after myocardial infarction. Obese Ossabaw swine were subjected to gradually developing regional coronary occlusion using an ameroid occluder placed around the left anterior descending coronary artery. Animals received subcutaneous injections of saline or liraglutide (0.005-0.015 mg/kg/day) for 30 days after ameroid placement. Cardiac performance was assessed at rest and in response to sympathomimetic challenge (dobutamine 0.3-10 µg/kg/min) using a left ventricular pressure/volume catheter. Liraglutide increased diastolic relaxation (dP/dt; Tau 1/2; Tau 1/e) during dobutamine stimulation (P < 0.01) despite having no influence on the magnitude of myocardial infarction. The slope of the end-systolic pressure volume relationship (i.e., contractility) increased with dobutamine after liraglutide (P < 0.001) but not saline administration (P = 0.63). Liraglutide enhanced the slope of the relationship between cardiac power and pressure volume area (i.e., cardiac efficiency) with dobutamine (P = 0.017). Hearts from animals treated with liraglutide demonstrated decreased ß1-adrenoreceptor expression. These data support that GLP-1 agonism augments cardiac efficiency via attenuation of maladaptive sympathetic signaling in the setting of obesity and myocardial infarction.


Asunto(s)
Gasto Cardíaco/efectos de los fármacos , Receptor del Péptido 1 Similar al Glucagón/agonistas , Hipoglucemiantes/administración & dosificación , Liraglutida/administración & dosificación , Infarto del Miocardio/tratamiento farmacológico , Obesidad/tratamiento farmacológico , Animales , Receptor del Péptido 1 Similar al Glucagón/fisiología , Corazón/efectos de los fármacos , Corazón/fisiopatología , Infarto del Miocardio/etiología , Infarto del Miocardio/fisiopatología , Obesidad/complicaciones , Obesidad/fisiopatología , Receptores Adrenérgicos beta 1/efectos de los fármacos , Porcinos , Simpatomiméticos/administración & dosificación , Resultado del Tratamiento , Función Ventricular Izquierda/efectos de los fármacos
4.
Exp Biol Med (Maywood) ; 242(17): 1643-1656, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-28343439

RESUMEN

In vitro studies of cardiac physiology and drug response have traditionally been performed on individual isolated cardiomyocytes or isotropic monolayers of cells that may not mimic desired physiological traits of the laminar adult myocardium. Recent studies have reported a number of advances to Heart-on-a-Chip platforms for the fabrication of more sophisticated engineered myocardium, but cardiomyocyte immaturity remains a challenge. In the anisotropic musculature of the heart, interactions between cardiac myocytes, the extracellular matrix (ECM), and neighboring cells give rise to changes in cell shape and tissue architecture that have been implicated in both development and disease. We hypothesized that engineered myocardium fabricated from cardiac myocytes cultured in vitro could mimic the physiological characteristics and gene expression profile of adult heart muscle. To test this hypothesis, we fabricated engineered myocardium comprised of neonatal rat ventricular myocytes with laminar architectures reminiscent of that observed in the mature heart and compared their sarcomere organization, contractile performance characteristics, and cardiac gene expression profile to that of isolated adult rat ventricular muscle strips. We found that anisotropic engineered myocardium demonstrated a similar degree of global sarcomere alignment, contractile stress output, and inotropic concentration-response to the ß-adrenergic agonist isoproterenol. Moreover, the anisotropic engineered myocardium exhibited comparable myofibril related gene expression to muscle strips isolated from adult rat ventricular tissue. These results suggest that tissue architecture serves an important developmental cue for building in vitro model systems of the myocardium that could potentially recapitulate the physiological characteristics of the adult heart. Impact statement With the recent focus on developing in vitro Organ-on-Chip platforms that recapitulate tissue and organ-level physiology using immature cells derived from stem cell sources, there is a strong need to assess the ability of these engineered tissues to adopt a mature phenotype. In the present study, we compared and contrasted engineered tissues fabricated from neonatal rat ventricular myocytes in a Heart-on-a-Chip platform to ventricular muscle strips isolated from adult rats. The results of this study support the notion that engineered tissues fabricated from immature cells have the potential to mimic mature tissues in an Organ-on-Chip platform.


Asunto(s)
Ventrículos Cardíacos/citología , Procedimientos Analíticos en Microchip/métodos , Miocitos Cardíacos/citología , Miocitos Cardíacos/fisiología , Ingeniería de Tejidos/métodos , Función Ventricular/fisiología , Animales , Diferenciación Celular , Células Cultivadas , Perfilación de la Expresión Génica , Dispositivos Laboratorio en un Chip , Contracción Miocárdica/fisiología , Ratas , Ratas Sprague-Dawley
5.
Am J Gastroenterol ; 112(4): 537-554, 2017 04.
Artículo en Inglés | MEDLINE | ID: mdl-28139655

RESUMEN

In this article, we review our multidisciplinary approach for patients with pancreatic cancer. Specifically, we review the epidemiology, diagnosis and staging, biliary drainage techniques, selection of patients for surgery, chemotherapy, radiation therapy, and discuss other palliative interventions. The areas of active research investigation and where our knowledge is limited are emphasized.


Asunto(s)
Antineoplásicos/uso terapéutico , Carcinoma Ductal Pancreático/terapia , Pancreatectomía/métodos , Neoplasias Pancreáticas/terapia , Pancreaticoduodenectomía/métodos , Grupo de Atención al Paciente , Radioterapia/métodos , Carcinoma Ductal Pancreático/diagnóstico , Carcinoma Ductal Pancreático/epidemiología , Carcinoma Ductal Pancreático/patología , Drenaje , Endosonografía , Humanos , Imagen por Resonancia Magnética , Estadificación de Neoplasias , Cuidados Paliativos/métodos , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/epidemiología , Neoplasias Pancreáticas/patología , Selección de Paciente , Tomografía Computarizada por Rayos X
6.
PLoS Comput Biol ; 11(4): e1004190, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25849553

RESUMEN

In biology, organization at multiple scales potentiates biological function. Current advances in staining and imaging of biological tissues provide a wealth of data, but there are few metrics to quantitatively describe these findings. In particular there is a need for a metric that would characterize the correlation and consistency of orientation of different biological constructs within a tissue. We aimed to create such a metric and to demonstrate its use with images of cardiac tissues. The co-orientational order parameter (COOP) was based on the mathematical framework of a classical parameter, the orientational order parameter (OOP). Theorems were proven to illustrate the properties and boundaries of the COOP, which was then applied to both synthetic and experimental data. We showed the COOP to be useful for quantifying the correlation of orientation of constructs such as actin filaments and sarcomeric Z-lines. As expected, cardiac tissues showed perfect correlation between actin filaments and Z-lines. We also demonstrated the use of COOP to quantify the consistency of construct orientation within cells of the same shape. The COOP provides a quantitative tool to characterize tissues beyond co-localization or single construct orientation distribution. In the future, this new parameter could be used to represent the quantitative changes during maturation of cardiac tissue, pathological malformation, and other processes.


Asunto(s)
Citoesqueleto de Actina/ultraestructura , Biología Computacional/métodos , Citoesqueleto/ultraestructura , Procesamiento de Imagen Asistido por Computador/métodos , Animales , Miocitos Cardíacos/química , Miocitos Cardíacos/citología , Ratas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA